Literature DB >> 6195826

Psoriasis therapy: a current perspective.

N J Lowe.   

Abstract

Psoriasis is a common papulosquamous skin disease which frequently presents a therapeutic challenge to physicians. Topical therapy with steroids, coal tars and anthralin are effective when used properly for many patients. More severely affected patients may require phototherapy using coal tars and anthralin plus ultraviolet radiation. Systemic methotrexate administration is indicated for some patients with severe skin and arthropathic psoriasis. Treatment using psoralen and long-wavelength ultraviolet phototherapy has recently been approved and is effective in many patients, but long-term safety remains a question. Synthetic retinoids are experimental drugs currently being evaluated for severe forms of psoriasis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195826      PMCID: PMC1010928     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  30 in total

1.  The effect of anthralin and its derivatives on epidermal cell kinetics.

Authors:  L B Fisher; H I Maibach
Journal:  J Invest Dermatol       Date:  1975-05       Impact factor: 8.551

2.  Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.

Authors:  J A Parrish; T B Fitzpatrick; L Tanenbaum; M A Pathak
Journal:  N Engl J Med       Date:  1974-12-05       Impact factor: 91.245

3.  Abnormal cell proliferation in psoriasis.

Authors:  G D Weinstein; P Frost
Journal:  J Invest Dermatol       Date:  1968-03       Impact factor: 8.551

4.  Autoradiographic analysis of turnover times of normal and psoriatic epidermis.

Authors:  G D Weinstein; E J Van Scott
Journal:  J Invest Dermatol       Date:  1965-10       Impact factor: 8.551

5.  Association of psoriasis with HLA-DR7.

Authors:  J L Tiwari; N J Lowe; W Abramovits; B R Hawkins; M S Park
Journal:  Br J Dermatol       Date:  1982-02       Impact factor: 9.302

6.  New coal tar extract and coal tar shampoos. Evaluation by epidermal cell DNA synthesis suppression assay.

Authors:  N J Lowe; J H Breeding; M S Wortzman
Journal:  Arch Dermatol       Date:  1982-07

Review 7.  Methotrexate guidelines--revised.

Authors:  H H Roenigk; R Auerbach; H I Maibach; G D Weinstein
Journal:  J Am Acad Dermatol       Date:  1982-02       Impact factor: 11.527

8.  Etretinate treatment for psoriasis inhibits epidermal ornithine decarboxylase.

Authors:  N J Lowe; R Kaplan; J Breeding
Journal:  J Am Acad Dermatol       Date:  1982-04       Impact factor: 11.527

9.  Cutaneous polyamines in psoriasis.

Authors:  N J Lowe; J Breeding; D Russell
Journal:  Br J Dermatol       Date:  1982-07       Impact factor: 9.302

10.  Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis.

Authors:  S Hammarström; M Hamberg; B Samuelsson; E A Duell; M Stawiski; J J Voorhees
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205

View more
  1 in total

1.  Cassia tora Linn Cream Inhibits Ultraviolet-B-Induced Psoriasis in Rats.

Authors:  Manmohan Singhal; Niraj Kansara
Journal:  ISRN Dermatol       Date:  2012-03-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.